GlassScriptPhysician profile
Athanasios Kostandinos Manole
NPI 1780002220
$8,790.14
in general payments reported to CMS, 2019-2025
31 companies · $3,011 in 2025
The $3,011 reported for 2025 was more than what 85% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.82 · 2021: $655 · 2022: $2,365 · 2023: $1,402 · 2024: $1,318 · 2025: $3,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Travel and Lodging: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,889.68 |
| Travel and Lodging | $841.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.80 | 2021-2025 | |
| Zimmer Biomet Holdings, INC. | $1,343.01 | 2022-2025 | Persona, Gel-One Cross-Linked Hyaluronate, Rosa |
| Medtronic, INC. | $1,318.60 | 2024-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Accurian |
| Nevro Corp. | $1,277.81 | 2022-2024 | Senza |
| Abbott Laboratories | $499.93 | 2022-2025 | Proclaim, Eterna |
| Globus Medical, INC. | $480.26 | 2025 | Senza |
| Astrazeneca Pharmaceuticals LP | $244.37 | 2022-2025 | Airsupra |
| Pfizer INC. | $199.61 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $195.43 | 2023 | Xeomin |
| Allergan, INC. | $188.34 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $182.93 | 2022 | |
| Grt US Holding, INC. | $143.48 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2025 | Caplyta |
| Alkermes, INC. | $121.85 | 2025 | Lybalvi |
| Biohaven Pharmaceuticals, INC. | $76.81 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $73.04 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $63.66 | 2021 | |
| Depuy Synthes Sales INC. | $54.94 | 2022-2025 | Monovisc, Orthovisc |
| Nalu Medical, INC. | $33.82 | 2024 | Nalu Neurostimulation System |
| Biohaven Pharmaceutical Holding Company LTD. | $32.27 | 2022 | |
| Medline Industries LP | $27.63 | 2021-2022 | |
| Spr Therapeutics, INC | $26.78 | 2024 | Sprint Pns System |
| Bioventus LLC | $25.26 | 2025 | Xcell |
| Ultragenyx Pharmaceutical INC. | $23.89 | 2022 | |
| Biodelivery Sciences International, INC. | $19.51 | 2021 | |
| Impel Pharmaceuticals INC. | $19.36 | 2023 | Trudhesa |
| Vertos Medical, INC. | $18.74 | 2023 | Mild Device Kit |
| Ibsa Pharma INC. | $18.42 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.58 | 2025 | Euflexxa |
| Vertex Pharmaceuticals Incorporated | $14.70 | 2024 | |
| Electronic Waveform Lab, INC. | $3.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Athanasios Manole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.